Clinical Cancer Research, Vol 2, Issue 1 147-154, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein

W Domagala, M Markiewski, B Harezga, A Dukowicz and M Osborn
Department of Pathology, Medical Academy, 1 Unii Lubelskiej St., 71344 Szczecin Poland.

The prognostic value of tumor cell proliferative activity as measured by the MIB-1 monoclonal antibody in invasive ductal not otherwise specified breast carcinomas was determined for 186 patients, including 111 with no axillary node involvement. The MIB-1 antibody detects the Ki-67 antigen in microwave-processed paraffin sections of the formalin-fixed tumors. The mean MIB-1 score was 16% for all tumors, 16% for the node-negative group, and 15% for the node-positive group. In univariate survival analysis, the MIB-1 score (dichotomized, </=10 versus >/=10%) predicted overall 5-year survival in all of these groups. The mean MIB-1 score was significantly higher in vimentin- and p53 protein-positive tumors (P > 0.001) than in negative ones. The impact of vimentin expression and of p53 positivity on the prognostic significance of the tumor cell proliferation rate was assessed. Vimentin was associated significantly with poor 5-year survival in the entire cohort, and a particularly strong association was found in the node-negative group. p53 had a weak but statistically nonsignificant influence on survival. In a multivariate analysis using the Cox proportional hazards model, vimentin (P = 0.0002) was the only independent prognostic factor in node-negative patients. In contrast, the MIB-1 score (P = 0.009) was the only independent prognostic factor in the node-positive group. Therefore, node-negative patients with vimentin-positive tumors and node-positive patients with tumors with high proliferation rates might be appropriate candidates for early adjuvant chemotherapy.

This article has been cited by other articles:

				G. Viale, M. M. Regan, M. G. Mastropasqua, F. Maffini, E. Maiorano, M. Colleoni, K. N. Price, R. Golouh, T. Perin, R. W. Brown, et al. Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer J Natl Cancer Inst, February 6, 2008; 100(3): 207 - 212. [Abstract] [Full Text] [PDF]

				M. Colleoni, N. Rotmensz, P. Maisonneuve, A. Sonzogni, G. Pruneri, C. Casadio, A. Luini, P. Veronesi, M. Intra, V. Galimberti, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer Ann. Onc., October 1, 2007; 18(10): 1632 - 1640. [Abstract] [Full Text] [PDF]

				B. Willipinski-Stapelfeldt, S. Riethdorf, V. Assmann, U. Woelfle, T. Rau, G. Sauter, J. Heukeshoven, and K. Pantel Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells Clin. Cancer Res., November 15, 2005; 11(22): 8006 - 8014. [Abstract] [Full Text] [PDF]

				M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]

				G. Arpino, R. Laucirica, and R. M. Elledge Premalignant and In Situ Breast Disease: Biology and Clinical Implications Ann Intern Med, September 20, 2005; 143(6): 446 - 457. [Abstract] [Full Text] [PDF]

				T Megha, F Ferrari, A Benvenuto, C Bellan, A V Lalinga, S Lazzi, S Bartolommei, G Cevenini, L Leoncini, and P Tosi p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin J. Clin. Pathol., June 1, 2002; 55(6): 461 - 466. [Abstract] [Full Text] [PDF]

				V. A. Spencer, S. K. Samuel, and J. R. Davie Nuclear Matrix Proteins Associated with DNA in Situ in Hormone-dependent and Hormone-independent Human Breast Cancer Cell Lines Cancer Res., January 1, 2000; 60(2): 288 - 292. [Abstract] [Full Text]

				E. Putz, K. Witter, S. Offner, P. Stosiek, A. Zippelius, J. Johnson, R. Zahn, G. Riethmuller, and K. Pantel Phenotypic Characteristics of Cell Lines Derived from Disseminated Cancer Cells in Bone Marrow of Patients with Solid Epithelial Tumors: Establishment of Working Models for Human Micrometastases Cancer Res., January 1, 1999; 59(1): 241 - 248. [Abstract] [Full Text] [PDF]